When it comes to recommending a strong bet/stock, Mercury Lab is another name in the pharma sector. Currently quoting at 420 it has small equity of mere 1.20 crore while its current book value is around 150. A dividend paying company with EPS of 29 (on TTM basis) it is a virtually debt free company with profit generating efficiency level of 15% ; margins being maintained net profit in the higher trajectory and sales not only being maintained but on the increase.
At the price to earning of mere 13 while industry if at 30, it is a clear buy for the target of 650 in the coming months for those who can master patience. As for management is not only alive to the growth but it is also investor friendly with CRR : DPR ratio of 95 :: 05.
Promoters hold around 73% of total shares the balance of shares are held by general public.
Invest n Enjoy !!